Lupin Limited , a global pharmaceutical leader, has announced a significant milestone in its sustainability journey, achieving an S&P Global ESG Score of 91. This score represents a substantial improvement from 17 in 2021 and places Lupin among an elite group of companies worldwide that have surpassed the 90-point mark.

Industry-Leading Performance

The company's ESG score of 91 stands well above the pharmaceutical industry average of 28, highlighting Lupin's commitment to sustainable and responsible business practices. This achievement marks a 15-point increase from the previous year, establishing Lupin as a frontrunner in sustainable growth within the pharmaceutical sector.

Key Improvements Across ESG Pillars

Lupin has made significant strides across all three ESG pillars:

Environmental

• Increased use of renewable energy
• Successful reduction in carbon emissions
• Achievement of water-positive operations

Social

• Promotion of diversity and inclusion initiatives
• Launch of community health programs
• Significant contributions to societal healthcare

Governance

• Enhanced transparency in business practices
• Strengthened corporate governance
• Instituted board-level oversight for ESG-related risks and opportunities

Executive Perspective

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin, commented on the achievement: "Achieving a score above 90 in the S&P Global ESG ratings is a rare global distinction, highlighting our unwavering commitment to sustainability. With a 15-point increase from last year, Lupin not only leads the pharmaceutical industry today but redefines and sets new standards for responsible growth."

Strategic Implications

This exceptional ESG performance is expected to have several positive implications for Lupin:

1. Enhanced reputation among stakeholders
2. Potential for improved access to capital from ESG-focused investors
3. Strengthened resilience against environmental and social risks
4. Alignment with global sustainability trends and regulatory expectations

Looking Ahead

As Lupin continues to integrate sustainability into its core business strategy, the company is well-positioned to maintain its leadership in responsible pharmaceutical practices. This achievement not only sets a new benchmark for the industry but also reinforces Lupin's commitment to creating lasting value for patients, communities, and stakeholders worldwide.

The company's focus on sustainable practices, coupled with its strong market position and innovative product pipeline, suggests a promising outlook for Lupin's long-term growth and impact in the global pharmaceutical landscape.

Lupin Limited , a global pharmaceutical leader, has announced record-breaking financial results for the second quarter, showcasing robust growth across key markets and improved profitability.

Financial Highlights

Lupin reported total revenue from operations of INR 7,048 crores for Q2, marking a significant 24% year-over-year growth. The company's EBITDA reached INR 2,138 crores, with margins expanding to 31.3%, up from 23.8% in the same period last year.

Market Performance

• U.S. Business: Grew by 47% YoY, reaching USD 315 million in sales.
• India Business: Core domestic formulations grew by 8.8% YoY, outperforming the Indian Pharmaceutical Market (IPM) growth.
• Other Developed Markets: Reported 19% YoY growth, with Europe as a standout performer growing at 26.8% YoY.
• Emerging Markets: Demonstrated 45% YoY growth, led by strong performances in Brazil and South Africa.

Key Developments

1. EBITDA Margin Guidance Raised: Lupin has increased its full-year EBITDA margin guidance to 25-26%, up from the previous 24-25%.

2. VISUfarma Acquisition: Lupin announced plans to acquire VISUfarma, expanding its European presence and specialty portfolio in ophthalmology.

3. U.S. FDA Approvals: Secured approvals for complex injectables, including generic Victoza®, Risperdal long-acting injectable, and Glucagon.

4. Biosimilars Pipeline: Targeting to have at least five biosimilar products in the U.S. market by fiscal year 2030.

5. Respiratory Portfolio Expansion: Investing USD 250 million in the U.S. for expanding respiratory product manufacturing capabilities.

6. Green Propellant Initiative: Adopting Honeywell Solstice® propellant for inhalers, aligning with environmental sustainability goals.

7. Oncology Manufacturing Expansion: Unveiled a dedicated Oncology Block at its Vizag facility in India, enhancing capabilities in high-potent API development and manufacturing.

Management Commentary

Vinita Gupta, CEO of Lupin Limited, stated, "We are truly delighted to announce a record quarter with total revenue from operations and EBITDA exceeding INR 7,000 cr and INR 2,100 crores, respectively, for the first time in our history."

Ramesh Swaminathan, Executive Director, Global CFO & Head of IT and API Plus SBU, added, "We've delivered positive results on most key financial metrics, be it growth, gross and operating margins, earnings per share, or leverage ratios. As a result, our ROCE is about 25% as at the end of Q2."

Future Outlook

Lupin remains focused on sustaining its growth momentum through:

• Continued expansion in complex generics and biosimilars
• Strategic investments in specialty portfolios, particularly in respiratory, neurology, and ophthalmology
• Leveraging the VISUfarma acquisition to strengthen its European presence
• Advancing its green propellant initiatives in respiratory products

The company's strong performance and strategic initiatives position it well for continued growth and value creation in the global pharmaceutical market.